Background/Aims: It is unclear whether 5-aminosalicylic acid (5-ASA) formulation is associated with treatment adherence in ulcerative colitis (UC). Thus, we aimed to investigate the adherence rate after switching from 5-ASA tablets to granules. Methods: This prospective study included 121 UC outpatients treated using 5-ASA tablets. They were grouped based on choice: Group 1 (continued with tablets) and Group 2 (switched to granules without regimen change). Group 2 was further divided into Group 3 (returned to tablets) and Group 4 (continued with granules). The patients completed a self-administered questionnaire regarding the treatment. The primary endpoint was change in adherence after switching to granules. Results: Seventy-nine patients continued with tablets, while 42 patients switched to granules. The adherence rate to the tablet was not significantly different between Group 1 and 2 before switching. In Group 2, switching to granules did not affect adherence. However, in Group 4, adherence significantly improved after switching to granules. Group 3 showed no significant change in adherence before and after switching from tablets. Full-time work and difficulty taking tablets were significant predictors of continuing with granules in Group 4. Conclusion: Patients who continued with 5-ASA granules showed significantly increased adherence, suggesting that patient-tailored drug formulations improved treatment adherence.

Journal Section:
Original Paper
Keywords:
Treatment adherence, Ulcerative colitis, 5-Aminosalicylic acid
1.
Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV: Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247–257.
2.
Kane S, Huo D, Aikens J, Hanauer S: Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39–43.
3.
Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K: Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 2013; 48: 1006–1015.
4.
Sonnenberg E, Siegmund B: Ulcerative colitis. Digestion 2016; 94: 181–185.
5.
Shale MJ, Riley SA: Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191–198.
6.
Mine S, Takeshima F, Akazawa Y, Matsushima K, Minami H, Yamaguchi N, Ohnita K, Isomoto H, Nakao K: Correlation of fecal markers with magnifying endoscopic stratification in patients with ulcerative colitis who are in clinical remission. Digestion 2018; 97: 82–89.
7.
Khan N, Abbas AM, Koleva YN, Bazzano LA: Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis 2013; 19: 1123–1129.
8.
Hawthorne AB, Rubin G, Ghosh S: Review article: Medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157–1166.
9.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2:CD000011.
10.
Desreumaux P, Ghosh S: Review article: Mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006; 24(suppl 1): 2–9.
11.
Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929–2933.
12.
Kane SV: Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577–585.
13.
Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL: Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535–1544.
14.
Becker U, Lindorff K, Andersen C, Ranlov PJ: Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221: 95–101.
15.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–3277.
16.
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–1884.
17.
Farup PG: Compliance with anti-ulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther 1992; 6: 179–186.
18.
Evans L, Spelman M: The problem of non-compliance with drug therapy. Drugs 1983; 25: 63–76.
19.
Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y: Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: A double-blind, double-dummy, randomized multicenter study. Inflamm Bowel Dis 2013; 19: 1681–1690.
20.
Bohm SK, Kruis W: Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol 2014; 7: 369–383.
21.
Jackson CA, Clatworthy J, Robinson A, Horne R: Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525–539.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.